Johnson & Johnson (JNJ) Shares Outstanding (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Shares Outstanding (Entity) came in at $2.4 billion in Q2 2026, little changed year-over-year from $2.4 billion in Q2 2025, and little changed quarter-over-quarter from $2.4 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Shares Outstanding (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Shares Outstanding (Entity) across 18 years of filings, most recently posting $2.4 billion for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) changed 0.06% year-over-year to $2.4 billion; the TTM figure through Jun 2026 stood at $2.4 billion (changed 0.06% YoY), while the FY2025 annual figure was $2.4 billion, changed 0.09% from the prior year.
- Shares Outstanding (Entity) came in at $2.4 billion for Q2 2026 at Johnson & Johnson, roughly flat from $2.4 billion in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $2.6 billion in Q2 2022 to a low of $2.4 billion in Q1 2025.
- Average Shares Outstanding (Entity) over 5 years is $2.5 billion, with a median of $2.4 billion recorded in 2025.
- Year-over-year, Shares Outstanding (Entity) slipped 7.93% in 2023 and advanced 0.09% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $2.6 billion in 2022, then decreased by 7.87% to $2.4 billion in 2023, then dropped by 0.05% to $2.4 billion in 2024, then rose by 0.09% to $2.4 billion in 2025, then dropped by 0.0% to $2.4 billion in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $2.4 billion in Q2 2026, $2.4 billion in Q1 2026, and $2.4 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 1.94 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 5.70 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 2.04 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 1.22 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 210.89 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 111.58 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 200.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 2.41 Bn |
| Mar 29, 2026 | 2.41 Bn |
| Dec 28, 2025 | 2.41 Bn |
| Sep 28, 2025 | 2.41 Bn |
| Jun 29, 2025 | 2.41 Bn |
| Mar 30, 2025 | 2.41 Bn |
| Dec 29, 2024 | 2.41 Bn |
| Sep 29, 2024 | 2.41 Bn |
| Jun 30, 2024 | 2.41 Bn |
| Mar 31, 2024 | 2.41 Bn |
| Dec 31, 2023 | 2.53 Bn |
| Oct 1, 2023 | 2.52 Bn |
| Jul 2, 2023 | 2.60 Bn |
| Apr 2, 2023 | 2.61 Bn |
| Jan 1, 2023 | 2.63 Bn |
| Oct 2, 2022 | 2.63 Bn |
| Jul 3, 2022 | 2.63 Bn |
| Apr 3, 2022 | 2.63 Bn |
| Jan 2, 2022 | 2.63 Bn |
| Oct 3, 2021 | 2.63 Bn |